Condition: Locally Advanced Head-and-Neck Cancer · Sponsor: University Hospital Heidelberg
After multimodal therapy of head-and-neck tumors, patients often develop local recurrence, locally progressive disease or second primary tumors. In this highly pre-treated patient cohort, therapeutic options are limited. Patients that are not candidates for salvage surgery may benefit from re-irradiation. Despite recent technical advances, re-irradiation is associated with severe side effects. Carbon ion Re-Radiotherapy (reCIRT) has shown encouraging results in retrospective analyses with moderate toxicity. In the current Phase-II CARE-trial, reCIRT and conventional photon re-irradiation in patients with recurrent or progressive locally advanced head-and-neck cancer will be assessed regarding toxicity/ safety, local progression-free survival, overall survival and quality-of-life.
This description comes directly from the study's public registry record.
Held Thomas, PD Dr. · 49 622156 · thomas.held@med.uni-heidelberg.de
Cornelia Jäkel, Dr. · 49 622156 · studienkoordination.rad@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| University Hospital of Heidelberg, Radiation Oncology | Heidelberg, Germany | Recruiting |
| Philips University Marburg | Marburg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04185974